- Home
- BSET vs CGTX Comparison
BSET vs CGTX Comparison
Compare BSET & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSET | CGTX |
|---|---|---|
| Founded | 1902 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 158.8M |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BSET | CGTX |
|---|---|---|
| Price | $15.39 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 22.8K | ★ 971.8K |
| Earning Date | 10-08-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $330,953,000.00 | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $17.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.58 | $0.22 |
| 52 Week High | $19.75 | $3.83 |
Technical Indicators
Market Signals| Indicator | BSET | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 50.62 |
| Support Level | $15.03 | $1.30 |
| Resistance Level | $15.92 | $1.77 |
| Average True Range (ATR) | 0.41 | 0.14 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 72.08 | 64.48 |
Price Performance
Historical ComparisonAbout BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.